⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428208 | 0.67 | — | — | |
| SCHEMBL387530 | 0.67 | — | — | |
| SCHEMBL1448773 | 0.67 | — | — | |
| SCHEMBL1397535 | 0.67 | — | — | |
| SCHEMBL119842 | 0.67 | — | — | |
| SCHEMBL4465626 | 0.67 | — | — | |
| SCHEMBL4463520 | 0.63 | — | — | |
| SCHEMBL884933 | 0.63 | — | — | |
| SCHEMBL4196570 | 0.62 | — | — | |
| SCHEMBL433729 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | claimed |
| CN-118005611-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-07-21 | — | — | US | claimed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| US-20210379211-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-12-09 | — | — | US | claimed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | claimed |
| EP-3186241-B1 | PROBES FOR IMAGING HUNTINGTON PROTEIN | CHDI FOUNDATION INC (US) | 2020-10-07 | — | — | EP | claimed |
| US-10471061-B2 | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-11-12 | — | — | US | claimed |
| US-20190030031-A1 | GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS | THE US OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-01-31 | — | — | US | claimed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| WO-2008125811-A1 | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | WO | claimed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| WO-2008093065-A1 | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | claimed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | claimed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | claimed |
| WO-2001049690-A1 | 9-AZABICYCLO[4.2.1]NON-2-ENE DERIVATIVES AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF BRISTOL (GB) | 2001-07-12 | — | — | WO | claimed |